WEST LAFAYETTE, Indiana, April 4, 2016 -- SSCI, a Division of Albany Molecular Research Inc. (AMRI), located in West Lafayette, Indiana, has further enhanced its capabilities in the areas of crystalline form indexing and single crystal structure determination, through the addition of the Rigaku Oxford Diffraction (ROD) SuperNova Diffraction System.
Pamela Smith, Ph.D., Senior Director and Site Head at SSCI, said, "The expanded capability enhances our early development support for rapidly targeting a crystalline form and provides our scientists with the ability to obtain valuable crystallographic information for the clients we serve."
The ROD SuperNova Diffraction System is a flexible system for small molecule 3D structure analysis and provides SSCI with state-of-the-art structure solution capability utilizing a high-performance combination of micro-focus x-ray source and HPAD detector. Having this instrument available in-house will provide SSCI’s scientists, who are skilled with growing single crystals of suitable size and quality, with another powerful tool to confirm crystalline form, composition and absolute configuration of the chemical structure. This capability will also allow high-quality x-ray powder diffraction data to be obtained on small amounts of powder samples providing important information about particle statistics and preferred orientation effects.
The system, which will be installed and operational by April 2016, provides direct access to high-quality single crystal structure data as a stand-alone service offering and will further enhance the valuable information that SSCI delivers from polymorph, salt and cocrystal screens. According to Brett Cowans, Ph.D., Director of Material Science at SSCI, this addition brings significant value to AMRI's clients.
"Having in-house single crystal diffraction capability coupled with SSCI's industry-leading expertise in solid-state chemistry, the resulting data and corresponding expert scientific interpretation will be at a standard that is unmatched in the contract solid-state and analytical services industry," Dr. Cowans said.
About SSCI
SSCI, a Division of Albany Molecular Research Inc., provides industry leading contract solid-state and analytical testing services and exists to help companies in the pharmaceutical, food, agrochemical, and other chemical industries develop better products and get them to market more quickly. Over the past quarter century, SSCI has provided comprehensive cGMP research and analytical services in the characterization and chemistry of solid materials, with particular expertise in small and large molecules being investigated for pharmaceutical use. As AMRI’s Center of Excellence for Solid State Chemistry, its offerings include early candidate support services (in vitro analysis, stability, solubility, dissolution, excipient compatibility), solid form screening and polymorph, salt and cocrystal screening, form selection, particle engineering (process development, particle size method development), property improvement, crystallization of difficult materials, process control, biochemical analysis, full analytical chemistry support including method development and validation, intellectual property consulting and litigation support, and related research activities. For information about SSCI’s services, please contact 1-800-375-2179 | www.ssci-inc.com.
About Albany Molecular Research Inc.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the life sciences industry to improve patient outcomes and quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, peptides, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
Pamela Smith, Ph.D., Senior Director and Site Head at SSCI, said, "The expanded capability enhances our early development support for rapidly targeting a crystalline form and provides our scientists with the ability to obtain valuable crystallographic information for the clients we serve."
The ROD SuperNova Diffraction System is a flexible system for small molecule 3D structure analysis and provides SSCI with state-of-the-art structure solution capability utilizing a high-performance combination of micro-focus x-ray source and HPAD detector. Having this instrument available in-house will provide SSCI’s scientists, who are skilled with growing single crystals of suitable size and quality, with another powerful tool to confirm crystalline form, composition and absolute configuration of the chemical structure. This capability will also allow high-quality x-ray powder diffraction data to be obtained on small amounts of powder samples providing important information about particle statistics and preferred orientation effects.
The system, which will be installed and operational by April 2016, provides direct access to high-quality single crystal structure data as a stand-alone service offering and will further enhance the valuable information that SSCI delivers from polymorph, salt and cocrystal screens. According to Brett Cowans, Ph.D., Director of Material Science at SSCI, this addition brings significant value to AMRI's clients.
"Having in-house single crystal diffraction capability coupled with SSCI's industry-leading expertise in solid-state chemistry, the resulting data and corresponding expert scientific interpretation will be at a standard that is unmatched in the contract solid-state and analytical services industry," Dr. Cowans said.
About SSCI
SSCI, a Division of Albany Molecular Research Inc., provides industry leading contract solid-state and analytical testing services and exists to help companies in the pharmaceutical, food, agrochemical, and other chemical industries develop better products and get them to market more quickly. Over the past quarter century, SSCI has provided comprehensive cGMP research and analytical services in the characterization and chemistry of solid materials, with particular expertise in small and large molecules being investigated for pharmaceutical use. As AMRI’s Center of Excellence for Solid State Chemistry, its offerings include early candidate support services (in vitro analysis, stability, solubility, dissolution, excipient compatibility), solid form screening and polymorph, salt and cocrystal screening, form selection, particle engineering (process development, particle size method development), property improvement, crystallization of difficult materials, process control, biochemical analysis, full analytical chemistry support including method development and validation, intellectual property consulting and litigation support, and related research activities. For information about SSCI’s services, please contact 1-800-375-2179 | www.ssci-inc.com.
About Albany Molecular Research Inc.
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the life sciences industry to improve patient outcomes and quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, peptides, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
